نتایج جستجو برای: ژن her2

تعداد نتایج: 30284  

2017
E. An C.-Y. Ock T.-Y. Kim K.-H. Lee S.-W. Han S.-A. Im W.-L. Liao F. Cecchi A. Blackler S. Thyparambil W. H. Kim J. Burrows T. Hembrough D. V. T. Catenacci D.-Y. Oh Y.-J. Bang

Background A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to accurately distinguish between GC patients who would and would not benefit from anti-HER2 therapies. ...

Journal: :International journal of molecular medicine 2007
Thuy Tran Anna Orlova Igor Sivaev Mattias Sandström Vladimir Tolmachev

The use of radionuclide molecular imaging enables the selection of patients for treatment using molecular medicine. Preclinical studies have demonstrated that a novel low-molecular-weight affinity ligand, Affibody molecule Z(HER2:342) can image the expression of HER2 with high sensitivity and specificity in tumour xenografts and has a potential for the selection of patients for treatment using ...

2017
Arianna Palladini Giordano Nicoletti Alessia Lamolinara Massimiliano Dall’Ora Tania Balboni Marianna L. Ianzano Roberta Laranga Lorena Landuzzi Veronica Giusti Claudio Ceccarelli Donatella Santini Mario Taffurelli Enrico Di Oto Sofia Asioli Augusto Amici Serenella M. Pupa Carla De Giovanni Elda Tagliabue Manuela Iezzi Patrizia Nanni Pier-Luigi Lollini

Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in human breast cancer. We studied their interaction in hybrid transgenic mice bearing human full-length HER2 and Delta16 (F1 HER2/Delta16) in comparison to parental HER2 and Delta16 transgenic mice. Mammary carcinomas onset was faster in F1 HER2/Delta16 and Delta16 than in HER2 mice, however tumor growth was slower, and m...

2016
Tomoaki Ohtsuka Masakiyo Sakaguchi Hiromasa Yamamoto Shuta Tomida Katsuyoshi Takata Kazuhiko Shien Shinsuke Hashida Tomoko Miyata-Takata Mototsugu Watanabe Ken Suzawa Junichi Soh Chen Youyi Hiroki Sato Kei Namba Hidejiro Torigoe Kazunori Tsukuda Tadashi Yoshino Shinichiro Miyoshi Shinichi Toyooka

HER2 is a receptor tyrosine kinase and its upregulation via activating mutations or amplification has been identified in some malignant tumors, including lung cancers. Because HER2 can be a therapeutic target in HER2-driven malignancies, it is important to understand the molecular mechanisms of HER2 activation. In the current study, we identified that cytokeratin 19 (KRT19) binds to HER2 at the...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Elda Tagliabue Andrea Balsari Manuela Campiglio Serenella M Pupa

IMPORTANCE OF THE FIELD Differential levels of HER2 expression in normal versus HER2-overexpressing breast carcinomas, together with the demonstration of a key role for HER2 in tumor progression, make HER2 an ideal target for specific therapeutic approaches. AREAS COVERED IN THIS REVIEW This review considers the clinical value of trastuzumab and lapatinib, the two HER2-targeted therapies appr...

Journal: :Journal of immunology 2000
J S Dela Cruz K R Trinh S L Morrison M L Penichet

Anti-HER2/neu therapy of human HER2/neu-expressing malignancies such as breast cancer has shown only partial success in clinical trials. To expand the clinical potential of this approach, we have genetically engineered an anti-HER2/neu IgG3 fusion protein containing GM-CSF. Anti-HER2/neu IgG3-(GM-CSF) expressed in myeloma cells was correctly assembled and secreted. It was able to target HER2/ne...

2016
Feng Chi Rong Wu Xueying Jin Min Jiang Xike Zhu

HER2 positivity has been well studied in various cancers, but its importance in non-small-cell lung cancer (NSCLC) is still being explored. In this study, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect HER2 and COX-2 expression in NSCLC tissues. Then, pcDNA3.1-HER2 was used to overexpress HER2, while HER2 siRNA and COX-2 siRNA were used to silence...

2011
Michail Ignatiadis Françoise Rothé Carole Chaboteaux Virginie Durbecq Ghizlane Rouas Carmen Criscitiello Jessica Metallo Naima Kheddoumi Sandeep K. Singhal Stefan Michiels Isabelle Veys José Rossari Denis Larsimont Birgit Carly Marta Pestrin Silvia Bessi Frédéric Buxant Fabienne Liebens Martine Piccart Christos Sotiriou

PURPOSE Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (BC). Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging. METHODS Spiking experiments with 6 BC cell lines were performed and blood samples from hea...

Journal: :Cancer research 1998
X G Gu M Schmitt A Hiasa Y Nagata H Ikeda Y Sasaki K Akiyoshi J Sunamoto H Nakamura K Kuribayashi H Shiku

To elicit specific cellular immune responses against cancer, the development of efficient devices to deliver tumor antigen peptides to the MHC class I pathway constitutes a central issue. We report here a novel formula of hydrophobized polysaccharide nanoparticles, which can deliver a HER2 oncoprotein containing an epitope peptide to the MHC class I pathway. A protein consisting of the 147 amin...

2014
Ji Soo Choi Hyun Ok Kim Eun-Kyung Kim Young Joo Suh Jung Hyun Yoon Hee Jung Moon Min Jung Kim

The purpose of this study was to assess the usefulness of HER2 levels in ultrasonographically guided fine-needle aspiration biopsy (US-FNA) aspirates of axillary lymph nodes (ALNs) in the determination of lymph node metastasis or the characterization of primary breast cancer, and to correlate the HER2 levels in US-FNA aspirates (FNA-HER2s) of metastatic ALNs with the HER2 statuses of correspond...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید